Skip to main content
logo
Kailera Therapeutics, Inc. (KLRA)
NASDAQ: KLRA · Real-Time Price · USD
17.54
-0.78 (-4.26%)
Aug 20, 2026, 3:30 PM EDT - Market open

Kailera Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-292.2-148.96-329.57
Depreciation & Amortization
0.390.310.08
Loss (Gain) From Sale of Investments
-3.62-1.73-
Stock-Based Compensation
20.0710.941.41
Other Operating Activities
3.142.44139.5
Change in Accounts Payable
16.734.693.01
Change in Other Net Operating Assets
33.8812.090.61
Operating Cash Flow
-221.62-120.21-184.95
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-2.09-2.09-0.39
Investment in Securities
-910.07-490.51-
Investing Cash Flow
-912.16-492.6-0.39

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Long-Term Debt Issued
-100-
Net Debt Issued (Repaid)
-100-
Issuance of Common Stock
669.030.1-
Other Financing Activities
-5.19-0.32-
Financing Cash Flow
1,163598.66448.11

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
28.93-14.15262.77

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-223.7-122.3-185.35
Free Cash Flow Growth
---
Free Cash Flow Per Share
-1.73-6420.52-
Levered Free Cash Flow
--59.89-
Unlevered Free Cash Flow
--59.89-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Change in Working Capital
50.6116.783.62
SEC Filings: 10-K · 10-Q